Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
Regression Toward the Mean01:52

Regression Toward the Mean

Regression toward the mean (“RTM”) is a phenomenon in which extremely high or low values—for example, and individual’s blood pressure at a particular moment—appear closer to a group’s average upon remeasuring. Although this statistical peculiarity is the result of random error and chance, it has been problematic across various medical, scientific, financial and psychological applications. In particular, RTM, if not taken into account, can interfere when researchers try to extrapolate results...
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimation of Lifetime Costs Among Insured Persons with HIV in the United States.

PharmacoEconomics - open·2025
Same author

Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.

Journal of managed care & specialty pharmacy·2024
Same author

Is There a Future for Value-Based Contracting?

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2020
Same author

Estimation of the Incremental Cumulative Cost of HIV Compared with a Non-HIV Population.

PharmacoEconomics - open·2020
Same author

Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment.

Patient preference and adherence·2019
Same author

Personalized medicine: are payers the weak link?

Personalized medicine·2018
Same journal

Early Feasibility Studies in Europe: A Multisite Qualitative Study of Operational Challenges and Site Selection Determinants at 6 University Hospitals.

Clinical therapeutics·2026
Same journal

Safety of Celecoxib in Elderly Patients With Osteoarthritis: A Real-World Analysis Based on the FAERS Database.

Clinical therapeutics·2026
Same journal

Reimagining Representation Across the Clinical Research Ecosystem: Part II of a Specialty Update on Advancing Diversity, Racial Equity, and Inclusion in Clinical Research.

Clinical therapeutics·2026
Same journal

Combined Effects of Nicorandil and Enhanced External Counterpulsation on Coronary Microcirculation and Exercise Capacity in Patients With Coronary Slow Flow Phenomenon: A Randomized, Controlled, 3-Arm Trial.

Clinical therapeutics·2026
Same journal

Phase 1 Study Evaluating Gefurulimab Pharmacokinetics and Safety Following Delivery Via Autoinjector or Prefilled Syringe With Needle Safety Device in Healthy Adults.

Clinical therapeutics·2026
Same journal

Evaluating Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Associated With Newer Antiseizure Medications Using FAERS and JADER Combined With Bioinformatics Exploration.

Clinical therapeutics·2026
See all related articles

Related Experiment Video

Updated: May 13, 2026

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

Comparative-effectiveness research: does it matter?

Joshua P Cohen1

  • 1Center for the Study of Drug Development, Tufts University, Boston, MA 02111, USA. joshua.cohen@tufts.edu

Clinical Therapeutics
|March 26, 2013
PubMed
Summary
This summary is machine-generated.

Comparative effectiveness research (CER) shows a modest impact on prescribing, reimbursement, and health outcomes. Increased funding and new models incorporating CER evidence are expected to intensify this influence.

Related Experiment Videos

Last Updated: May 13, 2026

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies
08:24

The Joint Effect of Social Comparison and Social Distance on Evaluation of Intertemporal Choice Outcomes in Event-related Potential Studies

Published on: August 25, 2023

Area of Science:

  • Health Services Research
  • Health Policy
  • Evidence-Based Medicine

Background:

  • Policy debates on comparative effectiveness research (CER) have primarily focused on evidence generation and funding.
  • Implementation of CER findings and their impact on clinical practice and outcomes have received less attention.

Purpose of the Study:

  • To examine the empirical and normative aspects of CER.
  • To assess the impact of CER on prescribing, reimbursement, cost-containment, and health outcomes.

Main Methods:

  • A non-systematic literature review was conducted.
  • Searched Medline using keywords "comparative effectiveness research" and "policy implications."

Main Results:

  • A significant gap exists between available evidence and current prescribing practices and patient choices.
  • There is a need for a more systematic evidence base in the U.S. to inform policy.

Conclusions:

  • Comparative effectiveness research (CER) currently has a modest impact on prescribing, reimbursement, cost-containment, and health outcomes.
  • The impact of CER is anticipated to grow with increased funding and the integration of novel models for steering clinical decisions.